InterContinental Hotels profit drops 26%
Middle East North Africa - Financial Network

Demand More is a registered trade mark of MENAFN.COM

 
 
  Quotes: US MENA   Enter Symbol: NewsLetter: Search News: advanced
 Home  |  MENAFN News  |  Global News RELATED: Global News Regional News News Search

InterContinental Hotels profit drops 26%  Join our daily free Newsletter

MarketWatch.com-Tuesday, November 10, 2009
Digg This Article: InterContinental Hotels profit drops 26% Share This Article: InterContinental Hotels profit drops 26% Add to Delicious Seed this article Buzz this article Add to Reddit Add to furl Add to stumbleupon Add to Mixx!

InterContinental sees times still tough, as profit falls 26%

Last Update: 4:25 AM ET Nov 10, 2009

MADRID (MarketWatch) -- InterContinental Hotels Group, the owner of the Holiday Inn hotels chain, on Tuesday reported a 26% fall in third-quarter profit, citing a "challenging" trading environment with room rates still under "considerable pressure."

Net profit attributable to shareholders for the group IHG fell to $67 million in the quarter, versus $91 million in the year-ago period, while revenue fell to $401 million, from $496 million a year ago.

The firm recorded exceptional operating costs of $44 million in the quarter, including a $21 million non-cash goodwill write-down and $18 million of severance costs.

Sales were down in all of its regions, with the biggest decline in the Europe, Middle East and Africa region, and a small gain in Asia Pacific.

Revenue per available room, an important gauge of performance known in the industry as RevPAR, fell 13.5% in the third quarter, with U.S. RevPAR falling 15.7%.

"The trading environment remains challenging," said Andrew Cosslett, chief executive of InterContinental Hotels. "We see signs of occupancy stabilising, but rate is still under considerable pressure across the board."

Hotel chains have been reducing expenses to cope with the impact of a recession that has cut into consumer and business travel globally. InterContinental said it would continue to focus on improving operational efficiency and remains on track for savings in regional and central cost of around $80 million in the full year 2009. The group reiterated it expects to save between $65 million and $70 million by the end of 2010, versus 2008.

InterContinental owns, manages, leases or franchises, through various subsidiaries, nearly 4,400 hotels and over 640,000 guest rooms in 100 countries and territories around the world. In the past several quarters, the company has been focused on revamping its Holiday Inn hotels and re-launching its brand, actions which Cosslett said are gaining pace.

"The partnership we enjoy with our owners has been a key factor in our system's resilience through this downturn and underpins our optimism for the future," said Cosslett. "This unique relationship combined with our global scale, diverse brand portfolio, fee based business model and powerful system positions us to lead the industry when the upturn comes."

Shares of InterContinental traded up 2.1% to 860 pence.

Simon French, analyst at Panmure, said it was encouraging to see InterContinental's RevPar down just 13.5%, against a 15.2% fall in the prior quarter.

In a note to investors, French noted that PricewaterhouseCoopers on Monday released its 2010 RevPar forecast for the U.S. market, predicting a -0.7% decline in RevPar.

"Given IHG's brands consistently outperform the market (e.g. by 1.2 percentage points in the third quarter) we think this supports our RevPar assumptions of flat year-on-year (growth) in 2010," he said.

"Over the medium-term we see material upside to our forecasts as IHG benefits from a global RevPar recovery, returns to profitability in the Americas managed division and restores its incentive fee in the large U.K. Holiday Inn portfolio," said French. The analyst has a buy rating on InterContinental with a 910 pence price target.



International Provider
Feb 09, 2010 Treasurys down on news of Greek rescue plan, MarketWatch.com
Treasury prices decline and yields rise for a second straight session, as investors show greater comfort with prospects for European stability, making them more willing to move holdings back into riskier assets and away from the relative safety of U.S. debt.
Feb 09, 2010 Germany working on Greek rescue plan: reports, MarketWatch.com
The German government is working on a rescue package for Greece, reports from Berlin said Tuesday, news that sent stocks and the euro rallying.
Feb 09, 2010 S&P 500 passes first test of major support, MarketWatch.com
At last week's low, the U.S. markets had suffered a severe downdraft, with the Dow industrials plunging 895 points across just 13 sessions. Yet in the wake of last week's carnage, two technical events emerged, supporting a very near-term bull case.
Feb 09, 2010 Greek banks recover as Europe stocks broadly flat, MarketWatch.com
Stocks in Europe trade mixed-to-slightly higher as worries about Greece's finances appear to abate and as earnings news is eyed.
Feb 09, 2010 U.S. stocks surge on possibility of Greek rescue, MarketWatch.com
U.S. stocks rally broadly Tuesday on mounting hopes that the European Union might be considering a rescue package for Greece.
Feb 09, 2010 Tuesday's biggest gaining and declining stocks, MarketWatch.com
Stocks seeing big moves in trading include AMR, Cerus and Electronic Arts.
Feb 09, 2010 S&P cuts B. of A., Citi outlook on bailout concern, MarketWatch.com
Standard & Poor's cuts the ratings outlooks for both Bank of America and Citigroup to negative from stable, saying that if Washington bails out the banks again, it may be less likely to do the same for the companies' bond holders.
Feb 09, 2010 ECB flight change boosts Greek rescue speculation, MarketWatch.com
Analysts say news Tuesday that the European Central Bank president will return early from Australia to attend a meeting of European Union leaders in Brussels is providing the euro and financial markets with a lift.
Feb 09, 2010 Drug stocks gain; Cell Therapeutics rebounds, MarketWatch.com
Drug stocks gain in early action while shares of Cell Therapeutics bounced back after diving almost 25% on Monday over concerns about its new non-Hodgkin's lymphoma treatment pixantrone.
Feb 09, 2010 Updates, advisories and surprises, MarketWatch.com
A roundup of the latest corporate earnings reports and what companies are saying about future quarters.
more...



Google
Terms of Service  |   Privacy Policy  |   Contact Us |   Advertise  |   About MENAFN  |   Career Opportunities  |   Feedback
Copyright ©2000 All Rights Reserved.